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Abstract Giant cell tumor of the larynx (GCTL) is a rare
entity; only 34 cases have been reported in the literature.
We report a case of GCTL in a 46 year-old male presenting
clinical, radiographic, histological and therapeutic features.
Previously reported cases are also reviewed.
Keywords Giant cell  Denosumab  Head and neck
surgery  Larynx
Introduction
Giant cell tumor of the larynx (GCTL) is a rare entity with
34 cases reported to date. Giant cell tumor (GCT) occurs
most frequently in the epiphysis of the long bones of patients
in their third decade and has a slight female predilection
[1, 2]. GCT of bone is a benign neoplasm with a 25 % rate of
recurrence [2]. Six to ten percent of GCTs exhibit malignant
features manifesting as high-grade sarcoma occurring at the
site of a prior benign GCT or as a sarcoma in juxtaposition to
the GCT [2]. No such association has been recorded in the
reported cases of GCTL [2, 3].
Case Report
A 46-year-old male was referred to the division of head
and neck surgery for evaluation of a left neck mass causing
dyspnea. He was otherwise healthy. He denied prior or
current tobacco use. A contrast enhanced computerized
tomographic scan showed an expansile destructive lesion
epicentered on the left thyroid ala with invasion of the
overlying strap muscles. The left glottic and supraglottic
tissues were involved (Fig. 1). The patient was taken to the
operating room for tracheotomy to protect the airway and a
subsequent laryngoscopic biopsy was performed. The
procedure was tolerated well by the patient and he was
discharged without event. Histopathologic review of the
material obtained by biopsy revealed only normal laryn-
geal mucosa. Ten days later the patient underwent an ul-
trasound-guided trans-cervical core biopsy of the mass.
The histopathologic features were interpreted as a giant
cell lesion consistent with either a GCT or a giant cell
granuloma (GCG) (Fig. 2). Blood chemistry studies
demonstrated normal levels of serum calcium. A left
hemilaryngectomy with frontolateral extension was plan-
ned with the intent of laryngeal preservation. Remaining
foci of tumor would be treated with denosumab. Due to
strap muscle infiltration by tumor, a supraclavicular pedi-
cle flap was used for reconstruction of the hemilaryngeal
defect. Gross examination of the resected specimen
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revealed a 4.5 9 4.0 9 3.5 cm nodular mass composed of
white-tan homogenous, rubbery tissue with a central
hemorrhagic focus (Fig. 3). Microscopic examination re-
vealed a cellular neoplasm composed of numerous uni-
formly distributed osteoclast-like giant cells separated by
uniform mononuclear cells whose nuclei resembled those
of the giant cells (Fig. 4). The tumor had breached the
confines of the bone and cartilage of the thyroid ala and
extended into the adjacent soft tissue. Scattered reactive
woven bone and occasional mitoses were noted. Micro-
scopic foci of tumor were identified at the margins. Based
upon the uniform distribution of the giant cells, a diagnosis
of GCT was made. The patient is currently being treated
with denosumab.
Discussion and Review of the Literature
GCT most commonly occurs in the epiphysis of the long
bones, having a predilection for females in their third
decade [1, 2]. These tumors are essentially benign, but may
be locally aggressive [2]. Significant rates of recurrence
have been reported [2]. Histologically, GCTs are composed
of a mixture of multinucleated giant cells and mononuclear
cells in a fibroblast rich, loose, hemorrhagic, vascular
stroma [2]. The nuclei of the giant cells are strikingly
similar to those of the monuclear cells [2]. Lau et al. [4]
demonstrated that the mononuclear component of GCT
expressed alkaline phosphatase and receptor activator of
Fig. 1 Computed tomography scan demonstrating an expansile
destructive lesion epicentered on the left thyroid ala with invasion
of the overlying strap muscles and involvement of the left glottic and
supraglottic tissues
Fig. 2 Histopathology hematoxcylin and eosin 9200 original mag-
nification. Core biopsy specimen showing giant cells, a mononuclear
population and extravasated erythrocytes
Fig. 3 Gross specimen. Nodular mass measuring 4.5 9 4.0 9
3.5 cm composed of white-tan homogenous, rubbery tissue with a
central hemorrhagic focus
Fig. 4 Histopathology hematoxcylin and eosin 9400 original mag-
nification. Resection specimen demonstrating numerous uniformly
distributed osteoclast-like giant cells separated by mononuclear cells
in a vascular stroma
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nuclear factor kappa-B ligand (RANKL), markers of os-
teoblast lineage, while the multinucleate component ex-
pressed tartrate-resistant acid phosphatase and vitronectin
receptor, markers of osteoclastic lineage.
The head and neck region is an infrequent site for GCTs,
which tend to involve the sphenoid, ethmoid and temporal
bones [3]. The first case of GCTL was reported by Wesely
in 1940 [5–8]. Since then a total of 33 additional cases have
been published [3, 5–18].
There is a strong male preponderance (8.5:1) with an
average age at diagnosis of 42 years [3, 5–18]. Of the
laryngeal structures, the thyroid cartilage is the most
common site of origin (21, 60 %), followed by the cricoid
cartilage (9, 26 %), the epiglottis (2, 6 %) and the soft
tissues of the larynx (2, 6 %) [3, 5–18]. The location of one
case was not specified [5–8] (Table 1).
The most commonly reported findings on physical exam
were dysphonia (16, 47 %) and a palpable neck mass (15,
44 %). These were followed by respiratory difficulty (6,
18 %) and dysphagia (5, 15 %). Other less common find-
ings included sore throat and changes in vocal cord mo-
bility. Four authors reported normal laboratory values for
Table 1 Cases of giant cell tumor of the larynx
Case Year Author Gender Age (years) Location Laterality Size (cm)
1 1940 Wessely Male 51 Cricoid
2 1951 Federova Male 35 Thyroid
3 1952 Wagemann Male 40 Cricoid
4 1958 Perrino Male 32 Cricoid
5 1966 Kaliteevskii Male 52 Thyroid
6 1968 Pohl Male 50 Thyroid
7 1969 Kohn Male 50 Epiglottis
8 1971 Rudert Male 53 Thyroid
9 1973 Goto Male 47 Thyroid
10 1975 Ribari Male 35 Cricoid ‘‘Walnut’’
11 1974 Kotarba Male 60 Epiglottis
12 1974 A. Coyas Male 67 Vocal cord Right ‘‘Hazel nut’’ and ‘‘chick pea’’
13 1976 Kubo Male 40 Cricoid
14 1976 John Hall-Jones Male 26 Thyroid Right 5.5
15 1979 Tsybyrne Male 34 Thyroid
16 1988 Borghese Male 28 Thyroid
17 1993 Murrell Male 42 Thyroid Left
18 1994 P. C. Martin Male 23 Thyroid Right 4
19 1995 D. M. Thomas Female 56 Cricoid Bilateral 2
20 1996 Jochen A. Werner Male 35 Thyroid 4.8
21 2000 Hinni Male 31 Thyroid Left 4
22 2001 Wieneke Male 26 Thyroid Right 4.2*
23 2001 Wieneke Male 37 Thyroid Left 4.2*
24 2001 Wieneke Male 37 Cricoid Right 4.2*
25 2001 Wieneke Male 40 Thyroid 4.2*
26 2001 Wieneke Male 44 Thyroid Left 4.2*
27 2001 Wieneke Female 53 Thyroid 4.2*
28 2001 Wieneke Male 57 Cricoid Bilateral 4.2*
29 2001 Wieneke Female 62 Thyroid Left 4.2*
30 2003 Wong Male 49 Thyroid Left 4
31 2006 Nishimura Male 31 Thyroid Right 4
32 2011 Rochanawutanon Male 29 Cricoid ST Left 4
33 2013 C. de la Fouchardiere Male 38 Thyroid Right 4
34 2014 Nota Male 59 Thyroid Left 3
35 2015 Current case Male 46 Thyroid Left 4.5
* Cases averaged by author
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serum calcium and three reported normal alkaline phos-
phatase levels, two of which also reported normal levels of
parathyroid hormone. In eleven cases a history of tobacco
use was elicited and was denied by all [3, 5–18].
The treatment modality was described in 32 of the 34
cases [3, 5–18]. The majority of cases were treated by sur-
gery alone (19, 56 %), ranging from local excision to total
laryngectomy. Eight cases were treated by surgery and ra-
diation (24 %), three by radiation alone (9 %) and one case
by surgery, radiation and chemo therapy (3 %) [3, 5–18].
Derbel et al. [18] recently reported the use of denosumab
following surgery in treating a single case of GCTL (3 %).
In seventeen cases at least one measurement of the tu-
mor was reported clinically, radiographically or by gross
examination [3, 5–8, 10, 13, 14, 16–18]. The average di-
mension was 4.0 cm. The microscopic descriptions were
those of classic GCTs consisting of multinucleated giant
cells and mononuclear cells with a stroma composed of
fibroblasts, marked vascularity, and hemorrhagic foci.
While two authors reported thyroid gland displacement by
the tumor [10, 18], there were no reports of infiltration of
the thyroid gland. Thirty-one cases involved the cartilagi-
nous structures of the larynx, two cases occurred in the soft
tissues and one case occurred in an unspecified location [3,
5–18]. It was reported that bone was identified in the mi-
croscopic specimens of twelve cases [5–9, 11–14, 16, 18].
This is of interest as aberrations in the maturation and
ossification process of cartilaginous structures has been
suggested as a possible etiologic factor in the development
of giant cell lesions [13]. Mitotic activity was reported in
seventeen cases [3, 4, 7, 8, 10, 11, 14, 15, 17, 19] but only
one of these commented on pleomorphism [9].
A total of 23 cases included follow up information,
which ranged from 3 months to 25 years, with an average
of 5 years 9 months [3, 4, 7–10, 12–15, 17, 18]. In 22 of
these cases, no recurrence or metastasis was reported [3, 4,
7, 8, 10, 12–15, 17, 18]. The case presented by Coyas et al.
[9] was reported to have both recurred and metastasized.
The initial presentation was that of a soft tissue mass on the
right true vocal cord. Radiographic studies showed the
tumor to be restricted to the soft tissues of the larynx with
no cartilaginous involvement. Following excision, the tu-
mor recurred twice. The patient subsequently underwent
radiation therapy after which a tumor of the skin overlying
the initial surgical bed developed. The tumor was excised
and showed the same giant cell histology as the previously
excised lesions. The authors considered this to represent
local metastasis [9]. It is likely that the multiple recur-
rences were related to incomplete excision, rather than
metastatic disease [13]. Rochanawutanon et al. [17] also
reported of a case of GCTL of the soft tissues. Their case
was initially treated by resection and showed no recurrence
or metastasis at 11 years [18].
Weineke et al. [3] suggest that GCTL appears to have a
less aggressive behavior than its long bone counterpart.
Our review of the literature would seem to confirm this
view. This, however, may be a reflection of the small
number of cases and limited follow-up.
The differential diagnosis for lesions containing nu-
merous osteoclast-like giant cells includes GCT, GCG
(also referred to as giant cell reparative granuloma), for-
eign body giant cell reaction, brown tumor of hyper-
parathyroidism and giant cell-rich osteosarcoma [3, 13]. In
the case of a foreign body giant cell reaction, the distri-
bution of the giant cells would be less regular, their number
fewer and they would aggregate around the foreign mate-
rial. The brown tumor of hyperparathyroidism can appear
grossly and microscopically similar to GCT and GCG [20].
It is therefore essential that the patient be evaluated to rule
out hyperparathyroidism. In addition to the presence of
giant cells, giant cell-rich osteosarcoma should demon-
strate the deposition of osteoid in irregular sheets or in a
lace-like distribution [22]. Additionally, the osteogenic
cells should show some degree of nuclear pleomorphism
[22].
As documented in the differential diagnosis of the core
biopsy specimen from our patient, the distinction of GCT
from GCG can present a challenge to the surgical pathol-
ogist. GCG of the head and neck most commonly occurs in
the mandible as a central lesion, is more common in fe-
males than males and has a predilection for those under
30 years [20]. Both lesions show the presence of numerous
giant cells and mononuclear cells, and a stroma rich in
fibroblasts and vasculature [3, 19, 20]. GCTs tend to ex-
hibit more uniform distribution of the giant cells as well as
giant cells that possess a greater number of nuclei (often
exceeding 20) [3]. Thomas et al. [14] reported a giant cell
lesion of the larynx that they diagnosed as giant cell
reparative granuloma. In their description of the histo-
pathology they mention that areas of the lesion demon-
strated features of GCT but the more irregular distribution
of giant cells was consistent with giant cell reparative
granuloma [14]. Similarly, our case showed somewhat of a
bi-phasic pattern.
At least two views concerning the nature of giant cell
lesions exist. One posits that GCT and GCG are two dis-
tinct entities. GCG occurs in a younger age group (20 vs.
30) and has a lower rate of recurrence (13–35 vs. 60 %)
[23]. Furthermore, only isolated cases of metastasis or
sarcomatous transformation have been reported with GCG,
as opposed to the 6–10 % rate of sarcomatous transfor-
mation and 2 % rate of metastasis seen in GCT [23, 24].
Waldron and Shafer [19] point out that these differences
may be related to earlier clinical detection and diagnosis in
the gnathic locations. They view GCT and GCG as a single
entity [19, 20]. Liu et al. [21] provide support for this
450 Head and Neck Pathol (2015) 9:447–452
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viewpoint by demonstrating that receptor activator of nu-
clear factor kappa-B (RANK) and RANKL (markers of
osteoclastic and osteoblastic differentiation) are expressed
on lesional cells of both GCT and GCG. Research by
Gomes and colleagues indicate these two diseases possess
separate molecular profiles. Mutation of the H3F3A gene
has been reported in 90 % of GCTs. Gomes et al. [25]
evaluated nine cases of GCG for this mutation and found
all cases to be negative further supporting the theory that
the two entities may indeed be distinct.
Treatment of GCT is an area of continued debate [26].
Localized control can often be achieved by wide resection
[26]. Based on our review, wide local resection is a suffi-
cient surgery for GCTL [3, 5–18]. However, this can be
problematic in cases where resection may leave a func-
tional deficit or encroach upon vital structures. Some have
advocated the use of radiation, but post-radiation sarcoma
is of concern [7, 16, 18]. An ideal treatment for GCT has
yet to be identified [26, 27].
Presently a multinational clinical trial is being con-
ducted to examine the efficacy of denosumab in the treat-
ment of GCT of bone [27]. Denosumab is a fully-human
monoclonal antibody that binds RANKL and inhibits
RANK-RANKL interactions [28]. RANK is expressed on
the surface of osteoclast precursors. In order to differentiate
into osteoclasts, their RANK receptors must interact with
RANKL that is expressed on osteoblasts. It is theorized that
this interaction is prevented by the presence of denosumab
[4, 27, 28]. The most recent data from this trial suggests
that denosumab is a viable alternative therapy for GCT of
bone when function-sparing surgery is not felt to be pos-
sible. While this treatment appears to be effective, 9 % of
patients have developed serious adverse side effects in a
phase two study. These included hypocalcemia (5 %), os-
teonecrosis of the jaw (1 %, two of three cases resolved),
serious infection (2 %), and a new primary malignancy
(1 %) [27]. The use of denosumab should be considered
with attention to the renal function of the patient since
renal dysfunction increases the risk of hypocalcaemia.
Additionally, there have been reports of atypical femoral
fractures seen in patients receiving denosumab therapy
[29]. However, no causal relationship is known, nor has
fracture been documented as a side effect of the medication
[29].
Derbel et al. [18] reported their experience in treating a
single case of laryngeal GCT with denosumab. Following
denosumab treatment, the decision was still made to resect
residual tumor by total laryngectomy. Histopathological
review of the resection specimen showed a complete ab-
sence of giant cells with ossification of the tumor bed [18].
Denosumab therapy was initiated for our patient 2 months
following surgery. The patient had no signs of disease re-
currence at their 8 months post-surgery follow-up visit.
Conclusions
GCTL is a rare entity with only 34 cases reported in the
literature. It has a marked predilection for adult males and
most commonly involves the thyroid cartilage. While it
appears to respond well to surgical resection, future non-
surgical therapies may be considered. We have presented
an additional case treated by surgery with adjuvant
denosumab treatment, reviewed the literature and dis-
cussed the clinical and epidemiological features as well as
the differential diagnosis and summary of various treat-
ment modalities.
References
1. Dahlin DC, Cupps RE, Johnson EW. Giant-cell tumor: a study of
195 cases. Cancer. 1970;25(5):1061–70.
2. Reid R, Banerjee SS, Sciot R. Giant cell tumours. In: Fletcher
CDM, Unni KK, Mertens F, editors. World Health Organization
classification of tumors. Pathology and genetics of tumors of soft
tissue and bone. Lyon: IARC Press; 2002. p. 309–13.
3. Wieneke JA, Gannon FH, Heffner DK, Thompson LD. Giant cell
tumor of larynx: a clinicopathologic series of eight cases and
review of the literature. Mod Pathol. 2001;14(12):1209–15.
4. Lau YS, Sabokbar A, Gibbons C, Giele H, Athanasou N.
Phenotypic and molecular studies of giant-cell tumors of bone
and soft tissue. Hum Pathol. 2005;36(9):945–54.
5. Werner JA, HarmsD, Beigel A. Giant cell tumor of the larynx: case
report and review of the literature. Head Neck. 1997;19(2):153–7.
6. Wong KK, Seikaly H. Giant cell tumour of the larynx: case report
and review of the literature. J Otolaryngol. 2004;33(3):195–7.
7. Nishimura K, Satoh T, Maesawa C, Ishijima K, Sato H. Giant cell
tumor of the larynx: a case report and review of the literature. Am
J Otolaryngol. 2007;28(6):436–40.
8. Nota J, Okochi Y, Watanabe F, Saiki T. Laryngeal giant cell
tumor: a case report and review of the literature. Case Rep
Otolaryngol. 2014;2014:5035947.
9. Coyas A, Anastassiades OT, Kyriakos I. Malignant giant cell
tumour of the larynx. J Laryngol Otol. 1974;88(8):799–803.
10. Hall-Jones J. Giant cell tumour of the larynx. J Laryngol Otol.
1972;86(04):371–81.
11. Ribari O, Elemer G, Balint A. Laryngeal giant cell tumour.
J Laryngol Otol. 1975;89(8):857–61.
12. Murrell GL, Lantz HJ. Giant cell tumor of the larynx. Ear Nose
Throat J. 1993;72(5):360–1.
13. Martin PC, Hoda SA, Pigman HT, Pulitzer DR. Giant cell tumor
of the larynx: case report and review of the literature. Arch Pathol
Lab Med. 1994;118(8):834–7.
14. Thomas DM, Wilkins MJ, Witana JS, Cook T, Jefferis AF,
Walsh-Waring GP. Giant cell reparative granuloma of the cricoid
cartilage. J Laryngol Otol. 1995;109(11):1120–3.
15. Iype EM, Abraham EK, Kumar K, Pandey M, Prabhakar J,
Ahamed MI, et al. Giant cell tumour of hyoid bone: case report.
Br J Oral Maxillofac Surg. 2000;38(6):610–1.
16. Hinni ML. Giant cell tumor of the larynx. Ann Otol Rhinol
Laryngol. 2000;109(1):63–6.
17. Rochanawutanon M, Praneetvatakul P, Laothamatas J,
Sirikulchayanonta V. Extraskeletal giant cell tumor of the larynx:
case report and review of the literature. Ear Nose Throat J.
2011;90(5):226–30.
Head and Neck Pathol (2015) 9:447–452 451
123
18. Derbel O, Zrounba P, Chassagne-Cle´ment C, Decouvelaere AV,
Orlandini F, Duplomb S, et al. An unusual giant cell tumor of the
thyroid: case report and review of the literature. J Clin Endocrinol
Metab. 2013;98(1):1–6.
19. Waldron CA, Shafer WG. The central giant cell reparative
granuloma of the jaws. An analysis of 38 cases. Am J Clin Pathol.
1966;45(4):437–47.
20. Neville BW, Damm DD, Allen CM, Bouquot JE. Oral and
maxillofacial pathology. 3rd ed. St. Louis: Saunders; 2008.
21. Liu B, Yu SF, Li TJ. Multinucleated giant cell in various forms of
giant cell containing lesions of the jaws express features of os-
teoclasts. J Oral Pathol Med. 2003;32(6):367–75.
22. Gonzales AL, Cates JMM. Osteosarcoma: differential diagnostic
considerations. Surg Pathol Clin. 2012;5:117–46.
23. Sciubba JJ, Fantasia JE, Kahn LB. Atlas of tumor pathology:
tumors and cysts of the jaws, vol. 3. Washington: Armed Forces
Institute of Pathology; 2001.
24. Mintz GA, Abrams AM, Carlsen GD, Melrose RJ, Fister HW.
Primary malignant giant cell tumor of the mandible: report of a
case and review of the literature. Oral Surg Oral Med Oral Pathol.
1981;51(2):164–71.
25. Gomes CC, Diniz MG, Amaral FR, Guimaraes BVA, Gomez RS.
The highly prevalent H3F3A mutation in giant cell tumours of
bone is not shared by sporadic central giant cell lesions of the jaws.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118:583–5.
26. Wang H, Wan N, Hu Y. Giant cell tumour of bone: a new
evaluating system is necessary. Int Orthop. 2012;36(12):2521–7.
27. Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S,
et al. Safety and efficacy of denosumab for adults and skeletally
mature adolescents with giant cell tumour of bone: interim ana-
lysis of an open-label, parallel-group, phase 2 study. Lancet
Oncol. 2013;14(9):901–8.
28. Boyce BF, Xing L. Biology of RANK, RANKL, and osteopro-
tegrin. Arthritis Res Ther. 2007;9(Suppl 1):S1.
29. Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E,
Krieg MA, et al. The effect of three or six years of denosumab
exposure in women with postmenopausal osteoporosis: results
from the FREEDOM extension. J Clin Endocrinol Metab.
2013;98(11):4483–92.
452 Head and Neck Pathol (2015) 9:447–452
123
